The new micromethod for yeast susceptibility testing, MYCOTOTAL, was evaluated with 10 reference strains in seven laboratories. Ready-to-use microtitration plates and the same synthetic medium were used with two dilutions of imidazoles, flucytosine, and amphotericin B, permitting the categorization of each strain as susceptible, intermediate, or resistant. The results were compared with the MIC for each reference strain, and the repeatability and reproducibility were evaluated. The yeasts tested presenting different patterns of susceptibilities in reference MICs included six strains of Candida albicans, two strains of Candida tropicalis, one strain of Candida parapsiosis, and one strain of Torulopsis glabrata. For 4,200 antifungal agent-yeast results, the repeatability was 99.3% and the reproducibility was 96.3%. The correlation between the reference MICs and the category results was 91.5% for seven laboratories (and 92.7% for six laboratories excluding the laboratory which did not follow exactly the same protocol). We observed only 7.9% minor discrepancies, 0.5% (0.29% for six laboratories) major discrepancies, and 0.1% uninterpretable results. The percentages of concording results were similar for each strain and each antifungal agent tested. The overall results indicated that MYCOTOTAL was a reliable and reproducible method, well correlated with reference MICs. This ready-to-use micromethod with the same medium for all antifungal agents would be an important step in the necessary standardization of yeast susceptibility testing.
It is widely accepted that infections caused by fungi have increased in terms of annual morbidity and mortality, mainly owing to the increased use of more effective cytotoxic and antibacterial agents. A variety of antifungal agents are now available for use in parental therapy of fungal infections, including the polyene antibiotic amphotericin B, the synthetic antimetabolite flucytosine , and the synthetic imidazoles-triazoles (2, 9, 21, 29, 31, 39, 46) . Unfortunately, resistance of yeasts to antifungal agents has become evident (10, 13, 17, 18, 20, 23, 37) . For all these reasons, the clinical laboratory now is assuming a greater role in the selection and monitoring of antifungal chemotherapy.
Despite many efforts, in vitro antifungal susceptibility testing remains problematic (8, 16, 25, 26, 32, 39, 42, 47) . In vitro test procedures with antifungal agents are similar in design to those with antibacterial agents, namely, serial dilutions and agar diffusion tests (39) . Numerous factors may influence the results including the organism being tested, the inoculum size, conditions of incubation, test format, and composition of test medium. Several problems depend on the antifungal agent to be tested: amphotericin B is light sensitive and water insoluble, 5-FC must be tested in synthetic media free of antagonistic substances, and imidazoles are highly subject to considerable variations in MICs owing to inoculum and method of testing. In addition, azole antifungal in vitro testing results are poorly correlated with in vivo drug effects, especially for ketoconazole and fluconazole (2, 21, 22, 29, 30, 34, 35, 38, 40, 43) . Recently, an * Corresponding author. improved method has been proposed based on azole-antibiotic interactions (28) . Unfortunately, the method did not work routinely when tested with a larger number of Candida strains and particularly with non-Candida albicans strains (36) . Results of a survey of antifungal susceptibility tests in the United States indicated a poor interlaboratory precision of broth dilution testing of 5-FC and amphotericin B (5 
MATERIALS AND METHODS
The yeast strains were chosen with regard to both their importance in human pathology and differences in their susceptibility patterns. The strains tested included eight reference strains and two wild strains isolated from patients with chronic mucocutaneous candidiasis (kindly provided by F. Riley [37] ). These strains were transmitted freeze-dried and with a code number to the seven laboratories. The origin of the strains and the reference MIC determined by the standardized micromethod are summarized in Table 1 .
The reference MIC for each strain was determined earlier as previously described (R. Guinet, IXth ISHAM Congress, Atlanta, Ga., 1985 [11] ). Briefly, microdilution plates were prepared with 11 dilutions of each antifungal agent ranging from 100 to 0.1 ,ug/ml, and one well for a control received the solvent. (Table 3 ). The reproducibility ranged from 92 to 99.5%, with a 96.3% average for the seven laboratories. When calculated for six laboratories, since laboratory 3 in Table 3 did not strictly follow the protocol, the reproducibility was 96.6%. The agreement of the results with the reference MICs was 91.5% (92.7% for six laboratories), with only 0.5% major discrepancies (0.29% for six laboratories) (Table 3) .
Thé concordance between MYCOTOTAL and the MICs for each-strain ranged from 76.4 to 97% (Table 4) , with no major discrepancies for four strains, 1.9% major discrepancies for Candida tropicalis CBS 94, and 22.9% minor discrepancies for C. albicans DAR (from Riley [37] ). The concordance between MYCOTOTAL and MICs for each antifungal'agent ranged from 86% for econazole and amphotericin B to 97% for ketoconazole (Table 5 ). Major discrepancies did not exceed 0.8%, and the most important minor discrepancies were observed for econazole, 5-FC, and amphotericin B ( Table  6 and show' that only five antifungal agent-yeast pairs had discrepancies over 5%, namely, C. tropicalis CBS 94 with econazole (5.1%), C. tropicalis CIM 104 with miconazole (6.9%) and econazole (6.9%) and C. albicans DAR with amphotericin B (9%) and econazole (11.7%). (1, 3, 4, 7, 8, 14, 15, 19, 21) achieved with normal and maximum dosages of systemic drugs (e.g., amphotericin B, 5-FC, miconazole, and ketoconazole), and under these conditions, it was possible to determine the category of the results. However, in some circumstances, the use of only two concentrations to determine the category of the result might be insufficient and the clinical susceptibility aiso must be interpreted in terms of site of infection since some drugs diffuse poorly in the central nervous system and others can concentrate in urine. Furthermore, for nonsystemic antifungal agents, the category result is very pessimistic since higher local concentrations of antifungal agents are usually obtained. Nevertheless, all the category results were compared with the MICs for the reference strains, giving an overall agreement of 91.5% for seven laboratories, which should be regarded as a highly acceptable performance for a ready-to-use micromethod. Indeed, it should be remembered that the finite limit of complete agreement when any reference method is compared with itself has been estimated to be 92% (45) . Furthermore, the highest levels of minor discrepancies were obtained with strain-antifungal agent combinations (Table 6 ) corresponding to MICs very near the critical concentrations used in MYCOTOTAL (Table 1) , and this could correspond to differences no greater than one dilution in the MIC determination. Again, this confirms the good reproducibility of the micromethod since for C. tropicalis CIM 104 and Torulopsis glabrata CBS 138, the MICs of five antifungal agents were very near the critical concentrations and the agreements were still 86 and 92%. The difficulties of determining reliable susceptibility data in traditional in vitro tests have been extensively reported (8, 9, 24, 25, 32, 39, 42, 47) , and only limited success in interlaboratory and intralaboratory standardization has been achieved (5, 8, 26, 33, 41) . The main reasons for variations in data include subjective difficulties in interpretation of cultures in which fungal growth is partially inhibited and objective variations in MIC with composition and pH of culture media, size of fungal inoculum, and the time at which the tests are read (6, 8, 16, 24-26, 39, 42, 47) . The collaborative study reported here confirms that the MYCOTOTAL micromethod is very easy to handle and to read with clear endpoints of growth. Furthermore, MYCOTOTAL is very reproducible, insensitive to inoculum effect, and independent of the incubation time since no differehce in susceptibility was observed after 2 or 3 days of incubation (data not shown). The method was also proved to be valuable for susceptibility testing of Cryptococcus neoformans and Aspergillus sp. (data not shown). This collaborative study demonstrates that the introduction of improved methodology for susceptibility testing of fungi can give consistent results allowing interlaboratory comparisons at a level never reached in the past. Furthermore, some evidence of correlations between susceptibility results with MYCOTOTAL and drug effects in vivo was previously shown (R. Guinet, IXth ISHAM Congress, Atlanta, Ga., 1985), and results obtained with strains isolated from patients with mucocutaneous candidiasis were in agreement either with minimum effective doses in vaginal and systemic experimental candidiasis for ketoconazole (34, 37) and ICI 153,066 or with the relative inhibition factors determined by Odds et al. (27, 31) . In addition, the recent study of Guinet (12) concerning the comparative susceptibility of 1,850 yeast strains belonging to eight species by the standardized micromethods showed good concordance with the in vivo efficacy of antifungal agents. Variations in the susceptibility pattern were observed with yeast species and among C. albicans and T. glabrata strains, although none were resistant to amphotericin B and only 6% were resistant to 5-FC. C. albicans was highly susceptible to imidazoles (0.8 to 2.5% resistant strains), whereas T. glabrata showed much higher resistance rates (18% for tioconazole and 70% for ketoconazole). Such results correlate well with the effects of the drugs in vivo (14, 30, 40) , and the relative resistance of T. glabrata infection to treatment with imidazoles is now widely recognized (9, 10, 23, 38).
In conclusion, the collaborative evaluation reported here indicates that the micromethod MYCOTOTAL constitutes a major improvement in yeast susceptibility testing. This standardized micromethod can be used in routine work even by unexperienced personnel since it is ready to use, insensitive to inoculum effect, easy to handle, and utilizes the same synthetic medium for al! antifungal agents. We believe that MYCOTOTAL wil be of considerable help in clarifying the confusing area of antifungal susceptibility testing. Despite these excellent results, the manufacturer must follow the evolution of antifungal drugs, and the most recent triazoles (fluconazole and itraconazole) should be introduced in the susceptibility test (2, 22, 29) . The introduction of a liquid dilution system could also improve the method, providing automatization and fungicidal testing as well as inhibitory testing. Finally, the actual indications of the MYCO-TOTAL susceptibility test can be used for all yeast isolates from deep mycoses and for all non-C. albicans isolates from superficial mycoses, but for C. albicans isolates from nonrecurrent superficial mycoses, the test is not useful owing to the great susceptibility in vitro (12) and in vivo to various imidazoles.
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